Market Executive Summary

The global Antisense and RNAi Therapeutics market was valued at US$ 1284.2 million in 2023 and is anticipated to reach US$ 1881.9 million by 2030, witnessing a CAGR of 5.5% during the forecast period 2024-2030.

Antisense therapy involves the use of synthetic nucleic acid molecules called antisense oligonucleotides (ASOs). These ASOs are designed to complement and bind to specific mRNA molecules, blocking their translation or leading to their degradation. This prevents the production of specific proteins that may be involved in disease processes. Antisense therapeutics can target a wide range of diseases, including genetic disorders, viral infections, and certain types of cancers.

RNAi is a natural cellular process that regulates gene expression by silencing or downregulating specific genes. RNAi therapeutics utilize this process by introducing small RNA molecules, such as small interfering RNA (siRNA) or short hairpin RNA (shRNA), into cells. These molecules target and bind to specific mRNA molecules, leading to their degradation and preventing the production of the corresponding proteins. RNAi therapeutics have shown potential in treating various diseases, including certain genetic disorders, viral infections, and cancer.

This report aims to provide a comprehensive presentation of the global market for Antisense and RNAi Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antisense and RNAi Therapeutics.

Antisense and RNA interference (RNAi) therapeutics are types of molecular therapies that target specific genes or gene products to treat various diseases. They work at the molecular level and aim to modulate gene expression to achieve therapeutic effects.

Report Scope

The Antisense and RNAi Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antisense and RNAi Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. 

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Antisense and RNAi Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Global Antisense and RNAi Therapeutics Companies Covered

Tekmira Pharmaceuticals, Arbutus Biopharma, Alnylam Pharmaceuticals, Antisense Therapeutics, Silence Therapeutics, Isis Pharmaceuticals, Sirnaomics, Santaris, Roche.

Global Antisense and RNAi Therapeutics Market, Segment by Type

RNA Interference

Antisense RNA

Global Antisense and RNAi Therapeutics Market, Segment by Application

Hospital

Clinic

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antisense and RNAi Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 12: The main points and conclusions of the report.